5 July 2021
The PRINCIPLE trial has been highly commended at the Health Data Research UK Awards for the way in which patient data is utilised so participants are contacted about the trial soon after receiving a positive test result.
23 June 2021
From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.
20 May 2021
Each year, International Clinical Trials Day recognises the people who conduct clinical trials, giving our community a chance to say thank you for everything they do to improve public health. This year our trials unit staff are sharing what makes them proud to be part of Oxford’s Primary Care Clinical Trials Unit.
12 April 2021
Inhaled budesonide, a common corticosteroid, is the world's first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. As of today, the treatment is available in UK primary care on a case-by-case basis.
Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial
8 April 2021
Could the antiviral favipiravir help transform COVID-19 into an illness that can be successfully treated by general practitioners?
3 March 2021
From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial
25 January 2021
Update from the Chief Investigators of the Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE), 25 January 2021
Inhaled corticosteroids to be investigated as a possible treatment for Covid-19 in national PRINCIPLE Trial
27 November 2020
In Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.
23 October 2020
The importance of patient and public contributors is recognised as key to the success of the study.
Britain’s most influential Hindu temple spreads awareness of the PRINCIPLE trial among Indian community
21 October 2020
Europe’s BAPS Swaminarayan Sanstha, the largest Hindu temple outside of India, is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.
1 October 2020
More than 1000 people across the UK have signed-up to take part in the UK-wide PRINCIPLE Trial of potential community-based treatments for COVID-19, led by Oxford University.
18 September 2020
Professor Mahendra G Patel, University of Bradford, joins PRINCIPLE Trial as National Black, Asian and minority ethnic Community and Pharmacy Lead
7 July 2020
There is no evidence to suggest a daily combination of probiotics reduces the need for antibiotics to treat acute infections in care home residents, finds a study led by Oxford University researchers published in JAMA.
17 April 2020
Researchers from Oxford University are now enrolling participants into the first clinical trial of potential COVID-19 treatments to take place in GP practices.
30 March 2020
The Nuffield Department of Primary Care Health Sciences at the University of Oxford and the Royal College of General Practitioners (RCGP) have joined forces with clinical system supplier EMIS Health to urgently recruit as many GP practices as possible for COVID-19 research.
11 February 2020
More than 18 percent of over 60's have chronic kidney disease (CKD), around 44 percent of whom are undiagnosed without screening, finds a study led by Oxford University researchers.
12 December 2019
A Europe-wide study conducted over three flu seasons finds that the antiviral drug, oseltamivir (Tamiflu®), can help people recover from flu-like illness about one-day sooner on average, with older, sicker patients who have been unwell for longer recovering two-to-three days sooner.